Accueil>>Peptides>>Calmodulin-Dependent Protein Kinase II 290-309

Calmodulin-Dependent Protein Kinase II 290-309

Catalog No.GC31170

Calmodulin-Dependent Protein Kinase II 290-309 est un puissant antagoniste de CaMK avec une IC50 de 52 nM pour l'inhibition de Ca2+/calmodulin-dependent protein kinase II.

Products are for research use only. Not for human use. We do not sell to patients.

Calmodulin-Dependent Protein Kinase II 290-309 Chemical Structure

Cas No.: 115044-69-4

Taille Prix Stock Qté
1mg
304,00 $US
En stock
5mg
1 195,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.

Peptide 290 to 309 is found to be a potent calmodulin antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase. Neither truncation from the amino terminus (peptide 296-309) nor extension in the carboxyl-terminal direction (peptide 294-319) markedly affects calmodulin binding, whereas shortening the peptide from the carboxyl terminus (peptide 290-302) or from both ends (peptide 295-304) results in the elimination of this activity[1].

[1]. Payne ME, et al. Calcium/calmodulin-dependent protein kinase II. Characterization of distinct calmodulin binding and inhibitory domains. J Biol Chem. 1988 May 25;263(15):7190-5.

Avis

Review for Calmodulin-Dependent Protein Kinase II 290-309

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Calmodulin-Dependent Protein Kinase II 290-309

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.